Northern Trust Corp Has $1.21 Million Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Northern Trust Corp grew its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 57.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,356 shares of the company's stock after purchasing an additional 36,643 shares during the period. Northern Trust Corp owned about 0.31% of Delcath Systems worth $1,208,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in DCTH. Quarry LP bought a new position in shares of Delcath Systems in the fourth quarter worth $34,000. Quantbot Technologies LP acquired a new stake in Delcath Systems during the fourth quarter worth about $66,000. Private Advisor Group LLC acquired a new stake in Delcath Systems during the fourth quarter worth about $153,000. Charles Schwab Investment Management Inc. bought a new position in Delcath Systems in the 4th quarter valued at about $156,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Delcath Systems by 1,161.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,694 shares of the company's stock valued at $177,000 after buying an additional 13,529 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $29.00 price target (up previously from $24.00) on shares of Delcath Systems in a report on Friday, May 23rd. Wall Street Zen upgraded Delcath Systems from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 24th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $24.00.

Delcath Systems Stock Performance

Shares of DCTH traded down $0.99 during mid-day trading on Friday, reaching $16.07. The company had a trading volume of 576,064 shares, compared to its average volume of 377,984. The company's 50 day simple moving average is $13.26 and its 200 day simple moving average is $13.12. The company has a market capitalization of $559.65 million, a price-to-earnings ratio of -11.90 and a beta of 0.72. Delcath Systems, Inc. has a 1-year low of $6.33 and a 1-year high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The firm had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. As a group, equities analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.